Replies to post #212591 on Innovation Pharmaceuticals Inc (IPIX)

[cabel]

That is exaclty what I was trying to say to Infinity!

Making investment choices based on results from small is risky, very risky. I don't deny that. But small P2 trials are a fact of life with almost all small biotechs. Don't make IPIX sound like an exception.

Anyway, I rather risk my money based on good results from a small trial than on bad results from the same trial. There is a difference.

He repeats over and over again that the data from P2a shows that P2b will fail,.. never a balanced obersavtion as you present.

Appreciate your posts!

[To infinity and beyond!]

I like your willingness to get into actual numbers, and look at the data

and yet, once again you are back to the percentages, which are- as you have carefully demonstrated-based on 6 and 4 responses(approx, we have to guess).

Yes they have enough data to do P2b, and sure, the world is full of small trials

But how many people are willing to make very large investments based on the P2a data?(Nota bene: of course I refer here to the average investor. It would apply to big pharma too)

My sense is that few or none are investing in IP for prurisol, and that most people are here for brilacidin, with some long term hope for kevetrin.

My guess is that you are not an investor here for prurisol, either, but there is room for hope.